

Prof. Dr. Hans Leuenberger, Institute of Pharmaceutical Technology, University of Basel Klingelbergstrasse 50, CH-4056 Basel Hans.Leuenberger@unibas.ch http://www.pharma.unibas.ch/technology/index.html. Water is a Solvent with unique Properties:



- Density of ice is lower than for liquid water
- High melting  $T_m$  and boiling temp.  $T_b$  at atmos.press.
- High amount of energy needed for evaporation of H<sub>2</sub>O
- $\Rightarrow$  Life exists only due to these unique properties

## Water is unique: Typical Data I



 $H_2O$  with Molecular weight M = 18 compared to  $C_3 H_6 S$  with Molecular weight 74 and with an *identical* dipole moment of  $\mu = 1.85$  Debye :

- $H_2O$ :  $T_b = 100 \,^{\circ}C$  at atmospheric pressure
- $C_3 H_6 S$ :  $T_b = 14 °C$  at atmospheric pressure

⇒ Unique properties not due to dipole moment

### Water is unique: Typical Data II



	H <sub>2</sub> O	H <sub>2</sub> S	H <sub>2</sub> Se	H <sub>2</sub> Te
Molecular Weight M	18	34	81	130
Melting Temp T <sub>m</sub> [°C]	0	- 85,6	- 65,4	- 51
Boiling Temp T <sub>b</sub> [°C]	100	- 60.8	- 41.5	- 3.8

⇒ Unique properties due to Hydrogen Bonding?

## Water is unique: Typical Data III



	H <sub>2</sub> O	H <sub>2</sub> S	H <sub>2</sub> Se	H <sub>2</sub> Te
Binding enthalpy H-X [kJ/mol]	464,4	338,9	305,4	267,8
Melting enthalpy [kJ/mol]	6,0	2,4	2,5	4,1
Evaporation enthalpy [kJ/mol]	40,7	18,7	19,9	23,9

⇒ Unique properties of water as a liquid: is it a "polymer"?

#### Water is unique: Structure



The *structure* of liquid water is *not very well known* and there is *no generally accepted theory* of liquid water:

- ⇒ it is assumed that there is a *dynamic formation* and dissolution of nanoclusters, *i.e. nano-icebergs* in liquid water.
- ⇒ Thus, liquid water has some "crystalline" properties and is partly highly structured (see next slides).





**(b)** 









#### Structure of Water: Consequences



The *structure* of water plays an important role in hydrophilic drug solutions (*solubilization* of drugs):

- $\Rightarrow$  it is assumed that cosolvents and the drugs dissolved partly distroy the original water structure thus *changing the unique properties* of water <sup>1,2</sup>
  - 1) A.Stengele, S.Rey and H. Leuenberger, A novel approach to the characterization of polar liquids part I: pure liquids, Int. J. of Pharm. 225, 123-134 (2001)
  - 2) A.Stengele, S.Rey and H. Leuenberger, A novel approach to the characterization of polar liquids, part II: Hydrophilic Solutions, Int. J. of Pharm. 241, 231-240 (2002)



- The energy released during the condensation of the vapor is responsable for the inactivation of the microorganisms exposed for a sufficient period of time.
- The inactivation process follows a first order kinetics

$$\frac{dN}{dt} = -k \cdot N$$

N = Number of microorganisms t = time k = kinetic constant



The inactivation process:

$$\frac{dN}{dt} = -k \cdot N$$

dN = Number of microorganisms inactivated per unit time dt k = kinetic constant

$$k = A \cdot e^{-\frac{E_a}{R \cdot T}}$$

The kinetic value k depends on the temperature T according to the law of Arrhenius.



The inactivation process:

$$k = A \cdot e^{-\frac{E_a}{R \cdot T}}$$

E<sub>a</sub> = (in)activation energy
R = Gas constant
A = Attempt frequency (unit t<sup>-1</sup>)

The kinetic value k (unit: t<sup>-1</sup>) depends on the temperature T according to the law of Arrhenius.



- It is *prerequisite* that the *pharmaceutical solutions* for steam sterilization are really *hydrophilic*, i.e. that *steam* can be *formed* and can *condensate* within the formulation.
- For an optimal heat transfer, i.e. an optimal antimicrobial treatment of surfaces of materials (containers etc.) to be sterilized it is a prerequisite that the autoclave contains only vapor and no air (check relationship temperature/pressure).



#### Do evacuate the autoclave before introducing steam

**Check:** Relationship between Temperature and Pressure





➡ Heat transfer of water vapor superior to hot dry air Relationship between Temperature and Pressure can be used for in-process control and validation purposes:

In case that the system should contain air and not only pure steam the resultant pressure is higher !

⇒ Thus all partial pressures contribute to the total pressure measured (Law of Dalton) !



Relationship between Temperature and Pressure can be used for an in-process control of steam sterilization

If the autoclave does not contain a vacuum pump for the evacuation of air, it is important that the air with its higher density can leave the autoclave through a valve at the bottom!

⇒ thus beakers to be sterilized should be put into the autoclave upside down, that the air is not trapped.

#### **Steam Sterilization**



#### Technical Remark: Vacuum facilitates evaporation and high pressure condensation



#### Inactivation of microorganisms



Exposure time D<sub>T</sub> = "Decimal reduction time"



#### D- and F-Value The Overkill - Method N = $10^{-6}$ F = n D<sub>T</sub> $\Rightarrow$ for N = $10^{-6} \Rightarrow$ F = ?, n = ?



Bacillus Stearothermophylus  $D_T = 1.5 \text{ min at } T = 121 \text{ }^\circ\text{C}$ , thus n = 10





*Inactivation* of *microorganisms* versus *Degradation* of the drug *substance*:



Both inactivation and degradation processes follow the law of Arrhenius !

$$k = A \cdot e^{-\frac{E_a}{R \cdot T}}$$

It is evident that the k values are different for both processes and depend on the respective  $E_a$  and A

#### For such a situation a continuous short-time high temperature sterilization process was developed (PhD-Thesis\*)

A. Mann<sup>1,2\*</sup>, M. Kiefer<sup>2</sup>, H. Leuenberger<sup>1</sup> J.Pharm. Sci. 90, 275-287(2001) <sup>1</sup> University of Basel, <sup>2</sup> Novartis Pharma Ltd., Basel

#### Continuous short-time high temperature sterilization process





Experimental set-up according to PhD Thesis Angelika Mann\* \* actual address: Novartis Pharma Ltd., Basel, Switzerland



Residence time for optimal sterilization process at T > 135 °C; Process parameters causing 12 log reduction of B. stearothermophilus spores (*dotted lines*) and causing < 0.5% drug degradation (*full lines*).

A. Mann<sup>1,2\*</sup>, M. Kiefer<sup>2</sup>, H. Leuenberger<sup>1</sup> J.Pharm. Sci. 90, 275-287(2001) <sup>1</sup> University of Basel, <sup>2</sup> Novartis Pharma Ltd., Basel

# Acknowledgements



#### Thank you for your Attention

Hans Leuenberger Institute of Pharmaceutical Technology University of Basel, Switzerland